trending Market Intelligence /marketintelligence/en/news-insights/trending/Lzmz0ZnVhlPcAwqx7ztKqw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Retrophin names CEO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Retrophin names CEO

Retrophin Inc. appointed Eric Dube president and CEO, effective Jan. 4.

Prior to joining Retrophin, Dube was president of North America at ViiV Healthcare, a GlaxoSmithKline PLC unit.

Dube succeeds Stephen Aselage, who is retiring. Aselage, who has been CEO since 2014, will continue to serve on Retrophin's board.

Dube will also serve on the board of the San Diego-based biopharmaceutical company, which develops therapies for rare diseases.